Feb 23, 2009 (Datamonitor via COMTEX) –
— Medtronic, a medical technology company, has received approval from the FDA for a humanitarian device exemption for its Reclaim deep brain stimulation therapy for chronic, severe obsessive-compulsive disorder.
The company also announced the first enrollment in its multi-center, randomized clinical trial of deep brain stimulation (DBS) for treatment-resistant depression.
Medtronic is proceeding with Read the rest of this entry »

(NYSE: MDT) on Thursday announced its official entrance into the psychiatric therapies field, with federal regulators approving an implanted device meant to treat severe obsessive-compulsive disorder.
Fridley-based Medtronic’s Reclaim Deep Brain Stimulation Therapy is a small pacemaker-like device that delivers electric charges to the brain.
The U.S. Food and Drug Administration approved the device under a “humanitarian device exemption.” Read the rest of this entry »

TUESDAY, Jan. 6 (HealthDay News) — The largest study of its kind finds that deep brain stimulation improves both physical function and quality of life after six months in patients with Parkinson’s disease.
Deep brain stimulation (DBS) performed better than currently available drug treatments, but it did carry some risks, including one death, according to a study in the Jan. 7 issue of the
.
“This basically corroborates what has largely emerged Read the rest of this entry »

Monday, December 15, 2008
,
is reporting that its deep brain stimulation device, the Intercept™ Epilepsy Control System, has been shown to “significantly reduced seizure frequency among patients with medically refractory epilepsy with partial-onset seizures.” According to a brief statement on the firm’s website, Medtronic will be seeking a premarket regulatory approval from the FDA for this system. We are guessing that the indication for Read the rest of this entry »